Role of circulating microRNA-132 in allergic bronchopulmonary aspergillosis: A case-control study

• Published in: Immunobiology (1979) 2021-05, Vol.226 (3), p.152074-152074, Article 152074
• Main Authors: Esawy, Marwa M., Baioumy, Shereen A., Ismail, Nagwan A., Shabana, Marwa A.
• Format: Article
• Language: English
• Subjects: Allergic bronchopulmonary aspergillosis; Aspergillosis, Allergic Bronchopulmonary - diagnosis; Aspergillosis, Allergic Bronchopulmonary - etiology; Biomarkers; Case-Control Studies; Circulating MicroRNA; Disease Susceptibility; Humans; IL-5; Liquid Biopsy; MicroRNAs - blood; MicroRNAs - genetics; miRNA-132; miRNA-21; Reproducibility of Results; Sensitivity and Specificity
• ISSN: 0171-2985; 1878-3279
• DOI: 10.1016/j.imbio.2021.152074

•miRNA-132 had significantly increased expression levels in SAFS and ABPA patients.•miRNA-132 had acceptable diagnostic performance criteria in ABPA detection.•miRNA-132 could be differentiate between ABPA and allergic asthma. Allergic bronchopulmonary aspergillosis (ABPA) is an allergic respiratory disease. In the current study, we aimed to evaluate the roles of miRNA-21 and miRNA132 as biomarkers in the diagnosis of ABPA. A total of 30 controls, 30 allergic asthmatic patients, 30 severe asthma with fungal sensitization (SAFS) patients, and 30 ABPA patients were included. Real-time polymerase chain reaction was used to quantify the level of miRNAs expression. The expression level of miRNA-21 was significantly higher in allergic asthmatic, SAFS, and ABPA patients in comparison with controls (p  0.05). The ABPA patients had significantly higher levels of miRNA-132 expression compared to controls, allergic asthmatic patients, and SAFS patients (p